ArticleFrontiers in genetics2026
An in silico protocol for predicting genetic biomarkers in rare diseases: a case study in sporadic amyotrophic lateral sclerosis.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studying the genetics of rare diseases is challenging because small sample sizes limit the statistical power of standard methods like Genome-wide association studies (GWAS). We created a new machine-learning approach to find candidate Single Nucleotide Polymorphisms (SNPs) when data is scarce. Our method trains a Random Forest model to spot similarities between SNPs. We used 189 known Sporadic Amyotrophic Lateral Sclerosis (sALS)-linked SNPs as positive examples and 938,544 unrelated SNPs as negatives. The model learns from genomic location, significance levels, nearby genes, and other features. When we tested it on sALS, it performed exceptionally well, with 93.8% accuracy and near-perfect AUC scores. The method uncovered 1,890 new SNP candidates for sALS. Among these, 209 reached genome-wide significance, and 50 appeared repeatedly in our analyses, making them strong candidates. Key genes like
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.